BioMarin shakes up executive team, tapping notable dealmaker James Sabry

BioMarin is bringing prominent dealmaker James Sabry onto its executive team, along with Amgen rare disease veteran Greg Friberg.

Sabry will start on Oct. 7 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Majority of patients with reflux disease do not have higher risk of cancer, study reports

Reflux disease manifests as acid regurgitation and heartburn and is a known risk factor for esophageal cancer.

September 13, 2023

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents – Psychedelic Alpha

TORONTO, July 28, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused

July 28, 2023

AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24

SAN DIEGO — AstraZeneca’s experimental PARP1 inhibitor helped shrink tumors in nearly half of people with breast cancers harboring certain DNA repair defects in an

April 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.